2017
DOI: 10.1590/s2175-97902017000300061
|View full text |Cite
|
Sign up to set email alerts
|

In silico pharmacodynamics, toxicity profile and biological activities of the Saharan medicinal plant Limoniastrum feei

Abstract: In-silico study was performed to find the pharmacodynamics, toxicity profiles and biological activities of three phytochemicals isolated from Limoniastrum feei (Plumbagenaceae). Online pharmacokinetic tools were used to estimate the potential of Quercetin, kaempferol-3-O-β-D-glucopyranoside (astragalin) and quercitin-7-O-β-D-glucopyranoside as specific drugs. Then the prediction of potential targets of these compounds were investigated using PharmMapper. Auto-Dock 4.0 software was used to investigate the diffe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
14
1
3

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
2
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(19 citation statements)
references
References 34 publications
1
14
1
3
Order By: Relevance
“…Similarly, astragalin was shown to cause morphological changes to the cell membrane in the parasite Trypanosoma cruzi (Marín et al, 2011[ 13 ]). Surprisingly, our finding was not in agreement with an earlier in silico study that predicted astragalin to function as membrane integrity agonist (Ammar, 2017[ 1 ]) indicating that in silico docking studies should be followed by at least some in vitro evaluations before predicting biological activities of different compounds.…”
Section: Resultscontrasting
confidence: 99%
See 1 more Smart Citation
“…Similarly, astragalin was shown to cause morphological changes to the cell membrane in the parasite Trypanosoma cruzi (Marín et al, 2011[ 13 ]). Surprisingly, our finding was not in agreement with an earlier in silico study that predicted astragalin to function as membrane integrity agonist (Ammar, 2017[ 1 ]) indicating that in silico docking studies should be followed by at least some in vitro evaluations before predicting biological activities of different compounds.…”
Section: Resultscontrasting
confidence: 99%
“…Likewise, changes in the expression levels of MDR1 due to astragalin treatment could not be detected since the strain did not have any basal expression of this gene (data not shown). Astragalin was shown to be a potential inhibitor of P-glycoprotein, a protein involved in efflux of drugs (Ammar, 2017[ 1 ]). Additionally, other kaempferol derivatives such as kaempferol-3-O-β-d-(6″-E-p-coumaroyl) glucopyranoside and kaempferol 3- O -α-L-(2,4-bis- E - p -coumaroyl) rhamnoside, were shown to inhibit NorA efflux pump of Staphylococcus aureus (Falcão-Silva et al, 2009[ 6 ]; Holler et al, 2012[ 9 ]).…”
Section: Resultsmentioning
confidence: 99%
“…Furthermore, astragalin can be absorbed by human intestines, but it is incapable of penetration to Caco-2 cells. Astragalin has been validated as a novel substrate of p-glycoprotein which is crucial for the metabolism and clearance of the compounds and for the efflux of drugs [ 154 ].…”
Section: Admet Profiles Of Astragalinmentioning
confidence: 99%
“…The target with prediction accuracy Pa > 0.9 was selected as the possible active target of the compound. 13 All parameters in the calculation process are set by system default.…”
Section: Target Screening Of Compoundmentioning
confidence: 99%